Cross-Cutting Engineering

Stability and Accelerated Aging

Evaluate how products, formulations, packages, and devices change under controlled conditions to support shelf-life and change-control decisions.

We use accelerated and real-time conditioning, scheduled pulls, chamber records, and paired performance or chemistry readouts to quantify trends over time.

ISO 17025ICH Q1A (R2)USP <659>FDA stability guidanceReviewed 2026-05-16
Request a quoteSubmit a sample

Purpose & when to use

ARE Labs supports stability and accelerated aging studies using environmental chambers, scheduled pull points, and paired performance or analytical readouts. These studies measure drift in products, formulations, devices, and packages over time. Programs can align with ICH Q1A (R2), USP <659>, and FDA stability guidance while maintaining ISO 17025 traceability for sample identity, chamber records, method controls, and reported uncertainty:

  1. ICH Q1A (R2) accelerated programs for inhalation products using environmental chambers and PSD or emitted-dose pulls to estimate early shelf-life risk.
  2. FDA stability guidance real-time programs for nasal sprays, aerosols, or devices using chamber storage and periodic performance or chemistry readouts.
  3. USP <659> storage-condition selection for packaged products using temperature/RH chambers, excursion logs, and defined pull schedules.
  4. ICH Q1B photo-stability or material-aging screens using UV exposure, retained samples, and paired chemistry or appearance checks.
  5. USP <1118> transport-stress linkage for packaged devices using cyclic abuse profiles, post-stress storage, and acceptance criteria.

Stability and accelerated aging support is useful when time, storage conditions, material changes, or shipping exposure could affect performance. The method plan defines the study conditions, pull schedule, paired tests, and evidence needed to inform shelf-life or design-change decisions.

Built for products, packages, and device programs

Stability programs cross pharmaceutical, device, packaging, and consumer-product boundaries. The same controlled-condition framework can support ICH, USP, FDA, and product-specific acceptance criteria.

  • Inhalation productsMDI, DPI, nebulizer programs
  • Nasal spraysPump and unit-dose formats
  • Consumer aerosolsSprays, valves, packages
  • Medical devicesMaterials and performance attributes
  • PackagingConfigurations and storage protection

Instrumentation & measurement ranges

ARE Labs selects conditioning and readout platforms for the protocol. The storage state, pull schedule, and paired test methods are documented before the study begins.

25 - 40 Cstorage

Environmental chambers (temperature/RH)

Controlled storage for real-time, intermediate, and accelerated programs with condition logging, chamber verification, and documented excursion handling.

20 - 60 Cexcursion

Cyclic stress and abuse protocols

Temperature cycling, humidity stress, and fit-for-purpose excursions used when shipping, distribution, or expected-use conditions may drive performance drift.

1 - 2 kLuxexposure

UV exposure for photo-stability

Optional light exposure for ICH Q1B-style photo-stability or material-aging questions when the product, package, or formulation has light sensitivity risk.

0 - 12 motrend

Paired performance and chemistry readouts

PSD, emitted dose, plume, VOC/by-product, HPLC assay, impurity, appearance, or package checks coordinated at defined pulls.

Test method options

MethodStrengthsTradeoffAligned with
Accelerated aging program (environmental chambers)
  • Faster drift signal from elevated temperature/RH conditions aligned to ICH Q1A (R2) and FDA stability guidance.
  • Supports early shelf-life estimates, formulation screens, and packaging comparisons before real-time data mature.
Requires documented acceleration assumptions, endpoint limits, and bounds for extrapolation.
ICH Q1A (R2)FDA stability guidance
Real-time stability program (scheduled pulls)
  • Most representative evidence for storage claims under ICH Q1A (R2), USP <659>, and FDA stability guidance.
  • Pull calendars, retains, chamber logs, and paired readouts create a traceable long-term record.
Decision timing is slower, so sample allocation and pull logistics must be disciplined.
ICH Q1A (R2)USP <659>FDA stability guidance
Photo-stability and material-aging screen (UV exposure)
  • Targets light-driven appearance, assay, impurity, or material changes under ICH Q1B / Q1C exposure framing.
  • Pairs exposed and protected samples so packaging protection or formulation sensitivity is visible.
Light exposure does not replace temperature/RH stability unless the protocol states that limited question.
ICH Q1B / Q1C
Transport stress linkage (cyclic abuse profiles)
  • Connects distribution excursions to post-stress performance under USP <1118> and product-specific acceptance criteria.
  • Useful for package changes, device revisions, and shipping-lane questions before full real-time data arrive.
Requires a defined stress profile and acceptance criteria before samples enter conditioning.
USP <1118>
Performance-plus-chemistry trending (paired readouts)
  • Links physical performance drift to assay, impurity, VOC, or by-product changes across pull points.
  • Supports ICH Q1B / Q1C package or container questions when configuration changes may affect stability.
Coordinated sampling increases method-control needs across storage, performance, and chemistry teams.
ICH Q1B / Q1C

Setup configurations

A stability study begins with a written protocol defining storage conditions, package configuration, pull timing, sample allocation, acceptance criteria, and readout methods. This setup connects the storage record to the tests performed at each pull, allowing trends to be interpreted against a documented sample history.

Environmental controls

Temperature/RH targets, chamber assignment, condition logging, calibration checks, and excursion review plan.

Sample numbers

Pull schedule, retain allocation, replicate count, destructive-test needs, and replacement rules for missed pulls.

Sample matrix

Formulation, device revision, packaging configuration, orientation, and storage state documented before conditioning.

Exposure profile

Accelerated, real-time, photo-stability, transport, or cyclic-stress profile selected for the decision under study.

Chain of custody

Receipt, storage transfer, pull execution, readout handoff, and final disposition recorded for each sample group.

Quality anchors for stability evidence

A stability program needs a clear regulatory posture before the first sample enters storage. These anchors define how the study frames storage conditions, pull records, acceptance criteria, and reporting.

  • ISO 17025AccreditedTesting-laboratory competence, traceable records, and method control.
  • ICH Q1A (R2)AlignedStability condition selection, pull timing, and shelf-life evidence.
  • USP <659>AlignedPackaging and storage condition terminology for articles.
  • FDA stability guidanceAlignedSubmission-facing stability expectations and documented rationale.

Key data outputs & reporting

Each stability program provides condition history, pull-point results, and trend interpretation in a format the customer can use for shelf-life, storage, design-change, or shipping decisions. Reports document the protocol, assumptions, acceptance criteria, chamber events, paired test methods, and contributors to uncertainty. Data are then organized by time, condition, lot, package, device revision, endpoint, and acceptance outcome.

Primary outputs

  • Trend tables for key performance attributes such as PSD, emitted dose, plume, appearance, VOCs, assay, or impurities.
  • Condition history, chamber excursions, pull execution records, and sample identity checks tied to each result set.
  • Shelf-life, re-test interval, or design-change discussion with assumptions, limits, and observed drift rates stated.

Deliverables

#FormatContents
01PDF reportProtocol, conditions, controls, results, trend interpretation, and stated assumptions.
02CSV / XLSX datasetsPull-point results, chamber logs, trend tables, and calculated deltas.
03FiguresTrend plots, overlays, excursion summaries, and condition comparisons.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Shelf-life appendix — Drift rates, confidence intervals, and shelf-life or re-test interval rationale.
  • Change-control pack — Side-by-side trends for package, material, formulation, or device revisions.
  • Transport linkage summary — Stress profile, post-stress checks, and comparison to unstressed retains.

QA / QC & data integrity

Stability data are useful only when the storage state and pull history are defensible. QA / QC controls cover chamber readiness, sample identity, pull execution, paired method controls, and exception handling from receipt through final reporting. The study file preserves the trend data along with the conditions that produced them.

Chamber calibration, verification, and continuous condition logs reviewed against the protocol.

Pull-point checklists, sample identity verification, and chain-of-custody records for every sample group.

Method QC for paired readouts, including controls, calibration checks, blanks, repeats, or recovery checks as applicable.

Defined acceptance criteria for chamber excursions, outliers, missed pulls, and trend flags.

Storage configuration photos or diagrams when orientation, package state, or device setup affects interpretation.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Product, quality, regulatory, packaging, and device teams often use stability data to decide how much time-based evidence is needed before a claim, submission, or change-control decision. These answers address accelerated and real-time programs, condition selection, pull-point testing, transport stress, and deliverables. Contact ARE Labs if your product, package, or regulatory frame requires a different study structure.

Q.Which is better, accelerated aging or real-time stability?
A.The two approaches answer different questions. Accelerated aging provides earlier signals of drift and estimates of risk, while real-time stability provides representative long-term evidence. Many programs use both, with the assumptions and limitations documented in the protocol and report.
Q.Can performance tests run at each pull?
A.Yes. Pull-point testing can include PSD, emitted dose, plume, VOC/by-product, appearance, assay, impurity, or package checks. We define the readouts before storage begins so the sample count and pull timing match the decision the study needs to support.
Q.How are conditions and pull points chosen?
A.We begin with the applicable ICH, USP, FDA, or product-specific framework, then adjust the study for product risk, expected drift, package configuration, and decision timing. The protocol documents the conditions, pull dates, acceptance criteria, and handling of excursions.
Q.Do you include shipping or transport stress?
A.Yes. A transport profile can be applied before storage or evaluated as a separate stress leg. When distribution-risk evidence is needed, post-stress performance is compared with unstressed retains.
Q.What do stability deliverables include?
A.Deliverables typically include a PDF report, CSV or XLSX datasets, trend plots, chamber logs, pull records, and a discussion of drift, uncertainty, and study assumptions. Change-control or shelf-life appendices can also be added.

Standards & guidance

ARE Labs scopes each stability and accelerated aging study around the product, the decision, and the applicable regulatory frame. ISO 17025 serves as the quality-system anchor for traceable testing, while study design can align with ICH, USP, and FDA stability guidance where applicable. The cards below identify standards commonly used for storage conditions, photo-stability, packaging, and transport-linked evidence.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, traceable records, calibration control, and uncertainty contributorsView standard ->Stability & Shelf Life - Aligned

ICH Q1A (R2)

Stability testing of new drug substances and products, including condition selection and pull timingView standard ->Stability & Shelf Life - Aligned

ICH Q1B / Q1C

Photo-stability and package-configuration stability considerations for light-sensitive or changed productsView standard ->Pharmacopeial - Aligned

USP <659>

Packaging and storage requirements terminology for articles and labeled storage conditionsView standard ->Pharmacopeial - Aligned

USP <1118>

Monitoring and interpreting distribution, storage, and transport conditions for pharmaceutical articlesView standard ->QA & Regulatory - Aligned

FDA stability guidance

FDA expectations for stability evidence, storage claims, and submission-facing documentationView standard ->

Related services & devices

Service

Dose Uniformity & Emitted Dose

Pairs with stability pulls when per-actuation dose or shot-to-shot variability may drift during storage.Read more ->Devices

Drug Delivery

Inhalation, nasal, and oral delivery devices often need stability evidence across formulation, actuator, or package changes.Read more ->Service

Particle Size Distribution (PSD) Testing

PSD trending can show aerosol performance drift at stability pulls for inhalation, nasal, and spray products.Read more ->Devices

Spray & Aerosol

Consumer sprays and aerosol packages use aging studies to evaluate valve, material, emission, or package drift.Read more ->